These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21697766)

  • 21. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
    Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
    J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abnormalities in body composition and nutritional status in HIV-infected children and adolescents on antiretroviral therapy.
    Ramalho LC; Gonçalves EM; de Carvalho WR; Guerra-Junior G; Centeville M; Aoki FH; Morcillo AM; dos Santos Vilela MM; da Silva MT
    Int J STD AIDS; 2011 Aug; 22(8):453-6. PubMed ID: 21795418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.
    Resino S; Palladino C; Lorente R; Micheloud D; Bellón JM; Larru B; Gutiérrez MD; de José MI; Polo R; Muñoz-Fernández MA;
    Pediatr Infect Dis J; 2010 Aug; 29(8):774-7. PubMed ID: 20375850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitochondria and HIV infection: the first decade.
    Cossarizza A; Troiano L; Mussini C
    J Biol Regul Homeost Agents; 2002; 16(1):18-24. PubMed ID: 12003168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery.
    Nasi M; Pinti M; Chiesa E; Fiore S; Manzini S; Del Giovane C; D'Amico R; Palai N; Campatelli C; Sabbatini F; Roccio M; Tibaldi C; Masuelli G; Mussini C; Ferrazzi E; d'Arminio Monforte A; Cossarizza A;
    Antivir Ther; 2011; 16(3):365-72. PubMed ID: 21555819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
    Zhou HY; Zheng YH; He Y; Chen Z; Liu M; Yin W; Liu C
    Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications.
    Tarr PE; Telenti A
    Antivir Ther; 2007; 12(7):999-1013. PubMed ID: 18018758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy.
    Haugaard SB; Andersen O; Pedersen SB; Dela F; Richelsen B; Nielsen JO; Madsbad S; Iversen J
    J Med Virol; 2005 Sep; 77(1):29-38. PubMed ID: 16032748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleoside analogues and HIV: the combined cost to mitochondria.
    Cherry CL; Wesselingh SL
    J Antimicrob Chemother; 2003 May; 51(5):1091-3. PubMed ID: 12668570
    [No Abstract]   [Full Text] [Related]  

  • 32. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
    Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.
    Maia BS; Engelson ES; Wang J; Kotler DP
    Clin Nutr; 2005 Dec; 24(6):971-8. PubMed ID: 16095765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients.
    Seminari E; Tinelli C; Minoli L; Sacchi P; Filice G; Zocchetti C; Meneghetti G; Bruno R; Maserati R
    Antivir Ther; 2002 Sep; 7(3):175-80. PubMed ID: 12487384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy.
    Cossarizza A; Pinti M; Moretti L; Bricalli D; Bianchi R; Troiano L; Fernandez MG; Balli F; Brambilla P; Mussini C; Viganò A
    J Infect Dis; 2002 Feb; 185(3):299-305. PubMed ID: 11807711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
    Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
    HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondria and lipodystrophy: where are we now?
    Gerschenson M
    Antivir Ther; 2003 Aug; 8(4):261-3. PubMed ID: 14518694
    [No Abstract]   [Full Text] [Related]  

  • 40. Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients.
    Ciccosanti F; Corazzari M; Soldani F; Matarrese P; Pagliarini V; Iadevaia V; Tinari A; Zaccarelli M; Perfettini JL; Malorni W; Kroemer G; Antinori A; Fimia GM; Piacentini M
    Antivir Ther; 2010; 15(3):377-90. PubMed ID: 20516557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.